alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
"['E2014K', 'E2419K']","[{'ncitCode': 'C48387', 'drugName': 'Everolimus'}]","['Advanced kidney cancer, unresectable pancreatic neuroendocrine carcinomas, subependymal giant cell astrocytomas in the context of tuberous sclerosis and certain breast cancers.']",LEVEL_3A,LEVEL_Fda3,"{'id': 900, 'code': '', 'color': 'Yellow', 'name': '', 'mainType': {'id': None, 'name': 'Bladder Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Bladder/Urinary Tract', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23551593', '24625776']",[],"Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) that is FDA-approved for the treatment of advanced kidney cancer, unresectable pancreatic neuroendocrine carcinomas, subependymal giant cell astrocytomas in the context of tuberous sclerosis and certain breast cancers. Although the E2419K and E2014K MTOR missense mutations are rare, one patient with urothelial carcinoma harboring this combination of mutations had an extreme durable response to the combination of everolimus and pazopanib (PMID: 24625776). While everolimus is ineffective in urothelial cancers in unselected patient populations, everolimus may be beneficial in patients harboring mTOR mutations (PMID: 23551593)."
['Oncogenic Mutations'],"[{'ncitCode': 'C48387', 'drugName': 'Everolimus'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['24631838', '27482884', '30327302', '26831717', '24622468']",[],"Everolimus and temsirolimus are inhibitors of the mammalian target of rapamycin (mTOR) that are FDA-approved for patients with advanced renal cell carcinoma (RCC). Retrospective studies of mTOR inhibitors in patients with metastatic renal cell carcinoma indicate that mutations in TSC1, TSC2, and mTOR are associated with response to treatment (PMID: 24622468, 26831717). Preclinical studies show that cancer cell lines with hyperactivating mTOR mutations are sensitive to mTOR inhibitor treatment as measured by decreased proliferation in cell line and xenograft experiments (PMID: 24631838, 27482884). However, one analysis of the RECORD-3 trial has indicated that PTEN status versus mTOR, TSC1 or TSC2 status may be the major correlative in response to treatment with everolimus (PMID: 30327302)."
['Oncogenic Mutations'],"[{'ncitCode': 'C1844', 'drugName': 'Temsirolimus'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['24631838', '27482884', '30327302', '26831717', '24622468']",[],"Everolimus and temsirolimus are inhibitors of the mammalian target of rapamycin (mTOR) that are FDA-approved for patients with advanced renal cell carcinoma (RCC). Retrospective studies of mTOR inhibitors in patients with metastatic renal cell carcinoma indicate that mutations in TSC1, TSC2, and mTOR are associated with response to treatment (PMID: 24622468, 26831717). Preclinical studies show that cancer cell lines with hyperactivating mTOR mutations are sensitive to mTOR inhibitor treatment as measured by decreased proliferation in cell line and xenograft experiments (PMID: 24631838, 27482884). However, one analysis of the RECORD-3 trial has indicated that PTEN status versus mTOR, TSC1 or TSC2 status may be the major correlative in response to treatment with everolimus (PMID: 30327302)."
